白蛋白结合型紫杉醇与传统溶剂型紫杉醇在卵巢癌治疗中的研究进展
作者：江浩;李芬琴;尹如铁;
Author：
收稿日期： 年卷（期）页码：2015,30(05):-620-622
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：白蛋白结合型紫杉醇;传统溶剂型紫杉醇;卵巢癌;化疗;不良反应;药动学;研究进展
Key words：
基金项目：
中文摘要
白蛋白紫杉醇是一种紫杉醇与白蛋白结合的全新紫杉醇制剂,传统溶剂型紫杉醇常以蓖麻油和无水乙醇作为助溶剂,两者在疗效和不良反应上都有差异。文中就二者在在卵巢癌治疗中的药动学、疗效及不良反应等方面做一综述。
参考文献
[1]Xiao K,Luo J,Fowler WL,et al.A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer[J].Biomaterials,2009,30:6006-6016.
[2]Micha JP,Goldstein BH,Birk CL,et al.Abraxane in the treatment of ovarian cancer:The absence of hypersensitivity reactions[J].Gynecol Oncol,2006,100:437-438.
[3]Gradishar WJ.Albumin-bound paclitaxel:A next-generation taxane[J].Expert Opin Pharmacother,2006,7:1041-53.
[4]Desai N,Trieu V,Yao Z,et al.Increased antitumor activity,intratumor paclitaxel concentrations,and endothelial cell transport of cremophor-free,albumin-bound paclitaxel,ABI-007,compared with cremophor-based paclitaxel[J].Clin Cancer Res,2006,12:1317-1324.
[5]Coleman RL,Brady WE,Mc Meekin DS,et al.A phase II evaluation of nanoparticle,albumin-bound(nab)paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian,fallopian tube,or primary peritoneal cancer:A Gynecologic Oncology group study[J].Gynecol Oncol,2011,122(1):111-115.
[6]Agheli A,Park SC,Huang CJ,et al.Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma[J].Anti-Cancer Drugs,2009,20:525-526.
[7]Winner EP,Berry DA,Woolf S,et al.Failure of higer-dose paclitaxel to improve outcome in patients with metastatic breast cancer:Cancer and leukemia group B trial 9341[J].J Clin Oncol,2004,22:2061-2068.
[8]Jain RK.Normalization of tumor vasculature:An emerging concept in antiangiogenic therapy[J].Science,2005,307:58-62.
[9]Makriyannis A,Guo J,Tian X.Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer[J].Life Sci,2005,77:1605-1611.
[10]Kranenburg O,Verlaan I,Moolenaar WH.Regulating c-Ras function.Cholesterol depletion affects caveolin association,GTPloading,and signaling[J].Curr Biol,2001,11:1880-1884.
[11]Trieu V,Frankel T,Labao E,et al.SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel(ABI-007)Taxol.[J].Breast Cancer Res Treat,2004,88(Sup 1):26-27.
[12]Szebeni J,Muggia FM,Alving CR.Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel:An in vitro study[J].Natl Cancer Inst,1998,90(4):300.
[13]腾小玉,管忠震,姚志文,等.晚期实体癌患者对不含聚氧乙烯蓖麻油注射用紫杉醇白蛋白纳米粒悬浮液的临床耐受性研究[J].癌症,2004,23(11):1431.
[14]De Leon MC,Bolla S,Greene B,et al.Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel[J].Gynecol Oncol Case Rep,2013,5:70-71.
[15]Fader AN,Rose PG.Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel[J].Gynecol Cancer,2009,19:1281-283.
[16]Desai N,Yao Z,Soon-Shiong P,et al.Evidence of enhanced in vivo efficacy at maximum tolerated dose(MTD)of nanoparticle paclitaxel(ABI-007)and taxol in 5 human tumor xenografts of varying sensitivity to paclitaxel[J].Proc Am Soc Clin Oncol,2002,21:462.
[17]Socinski MA,Bondarenko I,Karaseva NA,et al.Weekly nabpaclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer:Final results of a phaseⅢtrial[J].Clin Oncol,2012,30:2055-2062.
[18]Nicole Wiedenmann,David Valdecanas,Nancy Hunter,et al.130-nm Albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain[J].Clin Cancer Res,2007,13:1868-1874.
【关闭】
